HHLA2 and intrahepatic cholangiocarcinoma: Experiments have proved that HHLA2 has prognostic significance and is more widely expressed as an immune checkpoint compared with PD-L1 in intrahepatic cholangiocarcinoma 33, which prove the feasibility of HHLA2 as a new immune checkpoint in liver tumors.